Halozyme Therapeutics terminates its €2bn acquisition of Evotec.

Halozyme Therapeutics, a biopharmaceutical company, terminated its €2bn acquisition of Evotec, a drug discovery and development company. "We continue to believe that a combination of Halozyme and Evotec would create a leading, differentiated, global pharma services company, benefitting shareholders, patients and employees. However, to date, Evotec has been unwilling to engage with us to explore a potential combination and a company spokesperson has publicly commented that its goal is to remain an independent company. As a result, we are withdrawing our proposal to acquire Evotec for €11 per share in cash," Helen Torley, Halozyme President and CEO.